NASDAQ:TTHI Transition Therapeutics (TTHI) Stock Price, News & Analysis → The Weight Loss Pill That Could Disrupt a $32 Billion Industry (From Behind the Markets) (Ad) Free TTHI Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Share Share Today's Range$1.52▼$1.5250-Day Range N/A52-Week Range$0.66▼$2.75VolumeN/AAverage Volume70,238 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Transition Therapeutics alerts: Email Address Ad Behind the MarketsFidelity, Bezos, Goldman Bet Big on Tiny BiotechAre you ready for a major shift in the investment world? There's a new drug The Wall Street Journal is calling the "King Kong" of drugs.Don't miss out on the "next Ozempic" >>> About Transition Therapeutics Stock (NASDAQ:TTHI)Transition Therapeutics Inc. is a product-focused biopharmaceutical company. The Company's principal business activity is the researching and developing of therapeutic agents. The Company is developing therapeutics for central nervous system (CNS) and metabolic disease indications. The Company's technologies are focused on the treatment of agitation and aggression in Alzheimer's disease and diabetes. The Company's subsidiary, Transition Therapeutics Ireland Limited (Transition Ireland), is developing two drug candidates: neuropsychiatric candidate ELND005 and androgen deficiency candidate TT701. The Company's subsidiary, Waratah Pharmaceuticals Inc. (Waratah), is developing diabetes drug candidate TT401. The Company's other two entities provide development services in support of the clinical and non-clinical activities of Transition Ireland and Waratah.Read More Ad Behind the MarketsFidelity, Bezos, Goldman Bet Big on Tiny BiotechAre you ready for a major shift in the investment world? There's a new drug The Wall Street Journal is calling the "King Kong" of drugs.Don't miss out on the "next Ozempic" >>> TTHI Stock News HeadlinesFebruary 7, 2024 | ca.finance.yahoo.comAckman exits Lowe's after bet earned $1.3 billion for Pershing Square fundsDecember 5, 2023 | markets.businessinsider.comRelief Therapeutics Shifts Commercial Operations to Partnership Model, Focusing on Efficient Patient Access and R&D GrowthMay 8, 2024 | Behind the Markets (Ad)Fidelity, Bezos, Goldman Bet Big on Tiny BiotechAre you ready for a major shift in the investment world? There's a new drug The Wall Street Journal is calling the "King Kong" of drugs.September 17, 2023 | foxnews.comSchool hid teen's gender transition from parents, leading to runaway, abuse nightmare: lawsuitMay 31, 2023 | tmcnet.comTG Therapeutics Announces Data from the ULTIMATE IJanuary 21, 2023 | thestreet.comTransition Therapeutics to Pay Eli Lilly $1MSeptember 19, 2022 | benzinga.comTryp Therapeutics Appoints Jim O'Neill as Chief Financial OfficerSeptember 14, 2022 | yahoo.comGlobal Anti-Drone Market Report 2022: Development of Versatile and Scalable Anti-Drone Systems Presents OpportunitiesMay 8, 2024 | Behind the Markets (Ad)Fidelity, Bezos, Goldman Bet Big on Tiny BiotechAre you ready for a major shift in the investment world? There's a new drug The Wall Street Journal is calling the "King Kong" of drugs.September 7, 2022 | finance.yahoo.comCytoImmune Therapeutics Appoints Remus Vezan, M.D., Ph.D., as Chief Medical OfficerAugust 26, 2022 | nz.finance.yahoo.comWugen Appoints Natalie Mount, Ph.D., as Chair of the Board of DirectorsMay 20, 2022 | yahoo.comOcean County Prosecutor's Office takes over Lavallette Police DepartmentApril 4, 2022 | ca.finance.yahoo.comUS to end policy expelling migrants over CovidMarch 11, 2022 | lse.co.ukChallenger Energy appoints Trinidadian as new country headMarch 10, 2022 | yahoo.comZoë Kravitz Says Previous 'Batman' Movie Rejected Her As Too 'Urban'March 10, 2022 | yahoo.comAward-Winning Actor Scarlett Johansson Joins Dress for Success® Worldwide as Global Ambassador as it celebrates its 25th AnniversaryFebruary 3, 2022 | nz.finance.yahoo.comKvarta SIA, subsidiary of Hepsor AS in Latvia, signs 7.5 m€ loan agreement to finance the construction of development projectJanuary 14, 2022 | thestreet.comTransition Stock Gaps Up On Today's Open (TTHI)December 18, 2021 | ca.finance.yahoo.comNew Mask Rules In Malibu As State Mandate ReturnsNovember 10, 2021 | nz.finance.yahoo.comThe Benchmark Company Achieves Significant Milestone of 20 Senior Analysts and Will Expand Coverage to Over 350 CompaniesNovember 5, 2021 | nz.finance.yahoo.comEducationSuperHighway Study Reveals 18 Million American Households Have Access to the Internet But Can’t Afford to ConnectNovember 5, 2021 | au.finance.yahoo.comLiquidia Reports Third Quarter 2021 Financial Results and Provides Corporate UpdateNovember 5, 2021 | nz.finance.yahoo.comBiden To Parents With Kids 5 And Over: ‘Please Get Them Vaccinated’November 4, 2021 | au.finance.yahoo.comCareDx Completes Orderly Management TransitionNovember 4, 2021 | ca.finance.yahoo.comGZ6G Technologies Hires Helen Young as Director of Operations and IT Wireless Managed Network ServicesNovember 4, 2021 | sg.finance.yahoo.comIvy Brain Tumor Center Collaborates with GSK on New Phase 0 Clinical Trial to Evaluate Niraparib in Patients with Brain CancerNovember 4, 2021 | nz.finance.yahoo.comBazaarvoice names Zarina Lam Stanford as Chief Marketing Officer to drive market education and adoption of user-generated contentSee More Headlines Receive TTHI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Transition Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeNASDAQ SectorN/A Industry N/A Sub-IndustryN/A Current SymbolNASDAQ:TTHI CUSIPN/A CIK1399250 Webwww.transitiontherapeutics.com Phone+1-416-2607770FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report TTHI Stock Analysis - Frequently Asked Questions What other stocks do shareholders of Transition Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Transition Therapeutics investors own include Telaria (TLRA), Himax Technologies (HIMX), Link Motion (LKM), Petróleo Brasileiro S.A. - Petrobras (PBR), Achillion Pharmaceuticals (ACHN), AcelRx Pharmaceuticals (ACRX), Acacia Research (ACTG), AK Steel (AKS), ALU (ALU) and Ambarella (AMBA). This page (NASDAQ:TTHI) was last updated on 5/8/2024 by MarketBeat.com Staff From Our PartnersThe Department of Defense Has a New Drone ContractorThe Tomorrow InvestorFidelity, Bezos, Goldman Bet Big on Tiny BiotechBehind the MarketsElon Musk Secret Crypto Plot ExposedCrypto 101 MediaAI “wealth window” is closing June 25thParadigm PressShocking: One AI startup's revenue could surge 4,735%Manward PressGold Set to EXPLODE!Gold Safe ExchangeThe AI Stock that’s Disrupting Every IndustryStockEarningsThe #1 lithium battery stock to have on your radar in 2024!Smallcaps Daily Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Transition Therapeutics, Inc. - Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
